The Gynecologic Oncology Group conducted a randomized, phase 3 trial that compared intravenous paclitaxel plus cisplatin with intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel ...

Paclitaxel is a hydrophobic mitotic inhibitor with a powerful anti-cancer effect. It belongs to the group of taxanes (together with docetaxel), which are potent cytotoxic diterpenes derived from ...

Two major side-effects of paclitaxel therapy are frequent hypersensitivity reactions and neuropathy. Standard paclitaxel contains Cremophor EL as a solvent, thus requiring premedication with high ...

Aim: The COSTABRAX study evaluated the cost–effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) versus polyethylated castor oil-based standard paclitaxel (sb-paclitaxel ...

Results showed the ORR was 17.1% in the tovecimig plus paclitaxel arm compared with 5.3% in the paclitaxel alone arm. Topline data were announced from a phase 2/3 trial evaluating tovecimig in ...

WASHINGTON, DC—A sirolimus drug-coated balloon (DCB) is noninferior to paclitaxel-coated DCBs for the treatment of femoropopliteal artery disease, according to data from the SIRONA trial, the first ...

“We are highly encouraged by the robust efficacy signal and the tolerable safety profile observed with onvansertib plus paclitaxel in patients with mTNBC. The majority of the patients were ...